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Background: Special AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types
of human cancer. However, the role of SATB1 in human nasopharyngeal carcinoma (NPC) remains unknown. In the
present study, we sought to investigate the contribution of aberrant SATB1 expression in the progression of NPC
and its association with the Epstein Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1).
Methods: Immunohistochemical analysis was performed to detect SATB1 and LMP-1 protein in clinical samples,
and the association of SATB1 protein expression with patient clinicopathological characteristics and LMP-1
expression were analyzed. SATB1 expression profiles were evaluated in well-differentiated NPC cell line CNE1,
poorly-differentiated CNE2Z, undifferentiated C666-1 and immortalized nasopharyngeal epithelia NP-69 cells using
quantitative RT-PCR, western blotting and fluorescent staining. After inhibition the SATB1 expression by using SATB1
specific small interfering RNA in these cell lines, the change of cell proliferation was investigated by western
blotting analysis of PCNA (proliferating cell nuclear antigen) expression and CCK-8 assay, and the cell migration was
assessed by Transwell migration assay. Finally, the expressions of SATB1 and PCNA were examined in CNE1 cells
that forced LMP-1 expression by fluorescent staining and RT-PCR.
Results: Immunohistochemical analysis revealed that SATB1 protein expression was elevated in NPC tissues
compared to benign nasopharyngeal tissues (P = 0.005). Moreover, high levels of SATB1 protein expression were
positively correlated with clinical stage (P = 0.025), the status of lymph node metastasis (N classification) (P = 0.018),
distant metastasis (M classification) (P = 0.041) and LMP-1 expression status (r = 2.35, P < 0.01) in NPC patients. In
vitro experiments demonstrated that an inverse relationship between SATB1 expression and NPC differentiation
status, with SATB1 weakly expressed in NP-69 cells and CNE1 cells, and significant increasingly expressed in CNE-2Z
and C666-1 cells. Targeted knockdown of SATB1 expression obviously attenuated the proliferation and migration of
highly SATB1-expressing CNE2Z and C666-1 cells, but not NP-69 and CNE1 cells. Interestingly, forced LMP-1
expression in CNE1 cells led to a surprisingly increasing SATB1 expression and nuclear location, companying with
an up-regulated PCNA expression.
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Conclusions: Our results reveal that EBV LMP-1-mediated over-expression of SATB1 is associated with NPC
progression, suggesting SATB1 may represent a promising biomarker and therapeutic target for NPC.
Keywords: Nasopharyngeal carcinoma, Special AT rich sequence binding protein 1, Epstein Barr Virus-encoded
latent membrane protein 1, Progression, Proliferation, MigrationBackground
The nuclear factor special AT-rich sequence binding pro-
tein 1 (SATB1), which was cloned in 1992, is considered to
be a global chromatin organizer [1]. By providing a nuclear
architectural platform, SATB1 regulates gene expression by
promoting chromatin remodeling and regulating the levels
of histone acetylation and methylation [2,3]. Under normal
physiological conditions, SATB1 is highly expressed in
the thymus, with low levels also present in the testes,
fetal brain and osteoblasts; however, expression is virtually
undetectable in other tissues [4,5]. SATB1-null mice display
abnormal expression of numerous genes involved in T-cell
development [5], implying a critical role for SATB1 in the
maintenance of the immune system.
Recently, accumulating data suggests that over-expression
of SATB1 contributes to tumor progression [6]. Studies by
Han et al. revealed that SATB1 is over-expressed in aggres-
sive breast cancer cells and the level of SATB1 expression
had high prognostic significance. In this study, targeted
silencing of SATB1 led to altered expression of >1000
genes, predominantly controlling cell adhesion, signaling,
extracellular matrix formation and cell cycle [7]. This report
opened a new window regarding the role of SATB1 in
tumor biology, despite controversial studies [8,9]. To date,
high expression of SATB1 has been linked to the progres-
sion of human gastric cancer [10-12], ovarian carcinoma
[13], liver cancer [14-16], rectal cancer [17,18], laryngeal
squamous cell carcinoma [19], cutaneous malignant melan-
oma [20], and prostate cancer [21,22]. In contrast to these
reports, however, Selinger et al. reported that loss of SATB1
is associated with poor prognosis in lung squamous cell
carcinoma [23]. Thus, the role of SATB1 in tumorigenesis
remains unclear and requires further investigation.
Nasopharyngeal carcinoma (NPC) is a malignant cancer
derived from the nasopharyngeal epithelium. Over the
past decades, epidemiological studies have shown that
NPC appeared the unique prevalence features, including
regional, racial familial aggregation and Epstein-Barr virus
(EBV) infection status. NPC is one of the most common
malignant diseases in Chinese and persons of south-east
Asian descent, and the provinces of Guangdong, Guangxi,
Hainan, Hunan and Fujian are the five most endemic
areas in China [24]. Histologically, non-keratinizing
carcinoma accounts for >97% of NPC cases in endemic
areas [25]. Clinically, most NPC patients present with
cervical lymphadenopathy at primary diagnosis [26],which represents a more advanced stage. Therefore,
current approaches aimed at improving the rate of
early detection, diagnosis and treatment in NPC patients,
deserves significant attention.
NPC is an EBV associated carcinoma, and EBV-encoded
oncogene latent membrane protein 1 (LMP-1) contributes
to the carcinogenesis of NPC. Previous studies in our de-
partment focused on the role of the LMP-1 in the patho-
genesis of NPC [27-31]. In the present study, we aimed to
clarify the role of aberrant SATB1 expression in NPC
progression. We investigated the correlation between
SATB1 protein expressions with NPC patient clinico-
pathologic parameters. Furthermore, we analyzed the
expression of SATB1 in a panel of NPC cell lines charac-
terized by varied differentiation and LMP-1 expression
status. Using RNA interference (RNAi), we investigated
the effect of targeted knockdown of SATB1 on NPC cell
proliferation and migration. Finally, the expression of




Clinical, paraffin-embedded samples were obtained from
119 patients from the Affiliated Hospital of the Guangdong
Medical College (Zhanjiang, Guangdong, China) and
the People’s Hospital of Zhongshan City (Zhongshan,
Guangdong, China). All patients did not receive preopera-
tive radiotherapy or chemotherapy. The use of the human
tissue in this study was approved by the Ethics Council of
the Affiliated Hospital of the Guangdong Medical College
and the People’s Hospital of Zhongshan City for Approval
of Research Involving Human Subjects. Subjects comprised
NPCs (n = 95; 71 men, 24 women) and nasopharyngeal
epithelial hyperplasia (NEH, n = 24; 18 men, 6 women).
Clinical data of patients was reviewed based on the
pathology tumor–node–metastasis (pTNM) system (AJCC ⁄
UICC 2002). Among 119 cases, the clinicopathologic
variables of 115 patients were shown as described pre-
viously [27], and the remained 4 cases were newly in-
volved. NPC patients were diagnosed for the first time
at an average age of 42.9 years (range, 23–72 years). There
were 5 samples in stage I, 10 samples in stage II, 36 samples
in stage III, and 44 samples in stage IV. All NPC patients
were diagnosed with non-keratinizing carcinoma following
histological examination.
Table 1 Correlation between the clinicopathologic
characteristics and expression of SATB1 protein in NPC
and NEH
Clinical parameters n SATB1 expression χ 2 P value
high low
Histological types
NPC 95 62 33 8.065 0.005*
NEH 24 8 16
Smoking
Yes 45 30 15 0.743 0.785
No 50 32 18
Gender
Male 71 48 23 0.680 0.410
Female 24 14 10
Age
≧50 46 27 19 1.697 0.193
< 50 49 35 14
Clinical classification
I-II 15 6 9 5.015 0.025*
III- IV 80 56 24
T classification
T1 - T2 32 17 15 3.136 0.077
T3 - T4 63 45 18
N classification
N0 19 8 11 5.618 0.018*
N1-N3 76 54 22
M classification
M0 81 49 32 4.180Δ 0.041*
M1 14 13 1
NEH: nasopharyngeal epithelial hyperplasia, Δ Continuity corrected χ2 test.
* Significance as indicated.
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IHC was performed using monoclonal antibodies against
SATB1 (Cat. #2938-1, 1/100; Epitomics, Burlingame, CA,
USA) and LMP-1 (CS1-4, 1:50; DAKO Glostrup, Denmark).
The process of IHC was performed as stranded protocols.
Briefly, paraffin sections (5 μm) were prepared for immuno-
histochemical staining by heating sections in sodium citrate
buffer (pH 6.0, 10 mM), and endogenous peroxidases were
blocked by incubation in 0.3% H2O2. Sections then were
incubated with primary antibodies at 4°C overnight and
non-immune IgG was used as negative control. Anti-
genic sites were localized using a SP9000 kit and 3,3′-
diaminobenzidine (DAB) kit (ZSGB-BIO, Beijing, China).
The immunoreactive score (IRS) of SATB1 was calculated
as previously described [17,28]. In brief, the staining
intensity was classed as 0, negative; 1, weak; 2, moder-
ate and 3, strong. The percentage of SATB1-positive
cells was scored as 1, 0 – 9% positive cells; 2, 10 – 50%
positive cells and 3, >50% positive cells. Samples with a
sum IRS <6 were considered to display low expression
of SATB1, and samples with a sum IRS ≥6 were considered
to display high expression of SATB1. Scoring system for
LMP-1 was done according to Khabir et al. [29]. Briefly,
immunostaining intensity was rated as follows: 0, none;
1, weak; 2, moderate; and 3, intense. The percentage of
LMP-1-positive cells was score as 0, none seen in the
section; 1, 0 – 25% positive cells; 2, 26 – 50% positive
cells; 3, 51 – 75%; and 4, 76 – 100%. In the present
study, sections with a sum IRS ≥1 were considered to
be LMP-1 positive.
Cell culture
Well-differentiated NPC cell line CNE1 (LMP-1-), CNE1-
GL (ectopic expression of EBV-LMP-1 in CNE1 cells,
LMP-1+), poorly-differentiated CNE2Z (LMP-1-) and
undifferentiated C666-1(LMP-1+) and the immortalized
nasopharyngeal epithelial cell line NP-69 (LMP-1-) were
maintained as previously described [27,30]. Briefly, CNE1,
CNE2Z and C666-1 cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Thermo Scientific,
Beijing, China) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Thermo Scientific), 100 U/ml
penicillin and 100 μg/ml streptomycin (Solarbio Science
& Technology Co., Ltd, Beijing, China). CNE1-GL cell
line was maintained in DMEM containing 10% FBS,
100 U/ml penicillin, 100 μg/ml streptomycin and 1 μg/ml
puromycin. The immortalized NP-69 was cultured in
defined keratinocyte serum-free medium (cat. #10744-
019, Invitrogen, Life Technologies, Guangzhou, China)
supplemented with 5% heat-inactivated FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 0.2 ng/ml
recombinant epidermal growth factor. All cell lines
were cultured at 37°C in a humidified atmosphere with
5% CO2.RNA interference (RNAi)
Small interfering RNAs (siRNAs) were purchased from
RiboBio Co., Ltd. (Guangzhou, China). For RNAi exper-
iments, a cocktail of two pairs of independent siRNAs
targeting the SATB1(Accession: NM_002971.4) coding
region were used; si-SATB1-1 forward, 5′-GGAUAGUCU




A corresponding scrambled sequence (si-Control, Cat.
#siB05815) was used as a negative control. One day prior
to transfection, CNE1, CNE2Z, C666-1 and NP-69 cells
were seeded in 6-, 24- or 96-well plates supplemented
with complete medium without antibiotics. Sub-confluent
(60-70%) cells were transfected with siRNAs using
Lipofectamine™ 2000 (Invitrogen) in Opti-MEM medium
(Invitrogen). Following incubation of cells at 37°C in a
A B
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Figure 1 Representative photographs of SATB1 expression in samples of nasopharyngeal carcinoma (NPC) and non-cancerous
nasopharyngeal epithelial hyperplasia (NEH) were detected by immunohistochemistry. The immunohistochemical PV9000 method was
used to detect SATB1 protein expression in clinical samples. Non-immune IgG was used as a negative control. The expression and location of
SATB1 in cells was colorized with DAB and counterstained with hematoxylin. (A): IRS <6.0 in NPC. (B) & (C): IRS >6.0 in NPC. (D): IRS <6.0 in NEH.
(E): IRS >6.0 in NEH. (F): IgG control. Original magnification, 400×. Scale bars = 50 μM.
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replaced with complete cell culture media. Transfection
efficiency was confirmed by fluorescence microscopy
of cells transfected with Cy3-conjugated control oligos.
The cells were harvested at different time points after
transfection for the following experiments.
RNA extraction and reverse transcriptase PCR (RT-PCR)
Total RNA was extracted with Trizol reagent (Invitrogen,
Carlsbad, CA, USA). cDNA was synthesized using 1 μg
of total RNA and the to generate the first strand
cDNA by oligo(dT) 18 using the Fermentas RT System
(Cat. #K1622, Thermo Scientific). The levels of LMP-1
and SATB1 transcrtipts in various NPC cell lines were
assessed by semiquantitative PCR or quantitative PCR,
respectively. The primer pairs used for PCR were in-
cluded in the Additional file 1. Semiquantitative PCR
was performed with Mastercycler® Gradient Thermal cycler
(Eppendorf, Germany) at the annealing tempreture of 55°C
with total 32 cycles. Products of PCR were separated by1.5% agarose gel electrophoresis and visualized under
UV using InGenius LHR gel Documentation and ana-
lysis system (InGene, Fredrick, MO, USA). Quantita-
tive PCR was conducted using the LightCycler480
instrument (Roche (China) Ltd., Shanghai, China) in a
final volume of 20 μl, including 10 μl SYBR Green I
PCR Master Mix (TOYOBO, OSAKA, Japan), 0.4 μl
forward primer (10 μM), 0.4 μl reverse primer (10 μM),
2 μl cDNA and 7.2 μl dH2O. PCR amplification was
performed as follows; 95°C for 1 minute, then 40 cycles
of 95°C for 15 seconds, 60°C for 1 minute. The relative
abundance of SATB1 mRNAs were determined from
the CT values and plotted as the fold change com-
pared with the control groups. For all PCR analysis,
the transcription levels of β-actin were served as a
loading controls.
Western blotting
Cells were collected and lysed with RIPA lyses buffer





Figure 2 Expression of SATB1 mRNA and protein in various types
of NPC and immortalized NP-69 cell lines. (A): Well-differentiated
CNE1 cells, poorly- differentiated CNE2Z cells, undifferentiated C666-
1 cells and the immortalized non-cancerous NP-69 cells were
seeded in 24-well plates (n = 3) and harvested for analysis of SATB1
expression by quantitative reverse transcription polymerase chain
reaction (qRT-PCR). β-actin was used as a loading control. ** P <0.01
vs NP-69, △P <0.05 vs CNE1, # P <0.05 vs CNE2Z. (B): Western blotting
was used to detected SATB1 protein expression in CNE1, CNE2Z, C666-
1 and NP-69 cell lines. β-actin was used as a loading control.
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sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), and then proteins were transferred to the
polyvinylidene difluoride (PVDF) membranes (0.22 μM
pore size). After twice washed with TBST, the membranes
were incubated with 5% skimmed milk in TBST at 37°C for
1 hour, then the membrane were incubated with the primary
antibodies (SATB1, 1/500, Epitomics; Proliferating cell nu-
clear antigen (PCNA), 1/400, Santa Cruz, CA, USA; LMP-1,
1/400, DAKO Glostrup, Denmark; β-actin, 1/1000, Santa
Cruz) at 4°C overnight, After twice washed by TBST, the
membranes were incubated with horseradish peroxidase
(HRP)-conjugated secondary antibodies for 1 hour at 37°C.
Bands were visualized using enhanced chemiluminescence
(ECL) reagents (Thermo Fisher, Rockford, IL, USA) and
analyzed with gel analysis system (BIO-RAD VersDoc
TM5000MP System, Guangzhou, China). The expressions
of β-actin were used as loading control.
Immunofluorescence staining
Indirect immunofluorescence was performed on cells grown
on glass coverslips for 48 hours. Cells were incubated over-
night with primary SATB1 (rabbit-anti, 1/100; Epitomics),
PCNA (mouse-anti, 1/100; Cell Signaling Technology, Inc.,
Danvers, MA, USA) and LMP-1 (mouse-anti, 1/50; DAKO
Glostrup, Denmark) antibodies at 4°C. After twice washed
by 1 × PBS, antigenic sites were subsequently localized using
FITC- or TRITC-conjugated goat anti-rabbit or -mouse
IgG (1/100, Protein Tech Group, Inc., Chicago, IL, USA).
Diamidino-2- phenylindole (DAPI) was used to stain
the nuclei. Images were captured using a laser scanning
confocal microscope (TCS SP5, Leica, Germany).
In vitro cell proliferation assay
Cell proliferation was assessed 24 hours and 48 hours
post-transfection with siRNAs using the Cell Counting
Kit-8 (CCK-8) assay, in accordance with the manufacturer’s
instructions (Biyuntian, Jiangsu, China). Briefly, transfected
cells (4 × 103 per well) were seeded in 96-well plates and
cultured for either 24 hours or 48 hours, after washed with
1 × PBS, 10 μl CCK-8 reagent plus 100 μl basal DMEM
medium was added per well and incubated at 37°C for
2 hours. The optical density (OD) was subsequently mea-
sured using a microplate reader (Multiskan MKS, Thermo
Scientific, Waltham, MA, USA) by dual wavelength mode
(450/630 nm). Data represent the mean ± SD of three
independent experiments.
Transwell migration assay
In vitro cell migration assays were performed as previ-
ously described [30] using Transwell chambers (8-μm
polycarbonate membranes, BD Biosciences). In brief,
48 hours following transfection with si-SATB1, si-Control
or no transfection, cells were harvested in DMEMsupplemented with 0.5% FBS. 2 × 104 cells were seeded
in the upper chamber which was placed over the lower
chamber containing DMEM medium supplemented with
10% FBS. Migration was allowed to proceed for 12 hours
at 37°C, and insert membranes were fixed for 20 minutes
with 70% ethanol, and stained with 0.5% Eosin. Membranes
were washed with PBS and cut from the inserts. Cells on
the upper surface of the membrane were removed with a
cotton swab and membranes were mounted with glycerol.
The number of migrated cells on the lower surfaces of
the membranes was determined by counting fifteen rep-
resentative fields from triplicate inserts.
Statistical analyses
Statistical analyses were performed using PRISM Software
(GraphPad Software, CA, USA). χ 2 and continuity corrected
χ 2 test (when cells have expected count less than 5)
were used to analyze the comparisons of SATB1 and
LMP-1 expression in clinical samples; Data of in vitro
experiments were expressed as the mean ± SD. For analysis





















Figure 3 Representative fluorescence photographs of SATB1 and PCNA protein expression in various NPC cell lines and NP-69 cells.
Cells were grown on glass coverslips for 48 hours and incubated with primary rabbit-anti human SATB1 and mouse-anti human PCNA antibodies
overnight. The antigenic sites of SATB1 and PCNA were detected using FITC-, TRITC-conjugated goat anti-rabbit and anti-mouse IgG and analyzed









Figure 4 SATB1 specific siRNA cocktails inhibit SATB1 and PCNA proteins expression. After transfected CNE1, CNE2Z, C666-1 and NP-69
cells with a cocktails of siRNA (si-SATB1), control siRNA (si-Control) or untransfected (MOCK) for 48 hours, 40 μg total proteins were used to
examine SATB1 and PCNA proteins expression in these cells by western blotting analysis. β-actin was used as a loading control.
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Figure 5 Inhibition of SATB1 expression attenuates NPC cells proliferation. CCK-8 Assay was used to assess cellular viability of CNE1,
CNE2Z, C666-1 and NP-69 cells after 24 hours and 48 hours following transfection with cocktails of SATB1 siRNA (si-SATB1), control siRNA
(si-Control) or untransfected (MOCK). Values of optical density (OD) were obtained by the absorbance at the dual wavelengths 450/630 nM,
and the results indicating the cell viability were plotted as the percentage over controls (MOCK cells). * P <0.05, ** P <0.01 vs Mock or
si-Control–treated groups.
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performed. For multiple groups, ANOVA was performed
followed by the Student–Newman–Keuls test. P values
<0.05 were considered statistically significant.
Results
Over-expression of SATB1 protein is correlated with
clinicopathological features of human NPC
SATB1 protein expression was analyzed by immuno-
histochemistry in tissues from 24 patients with NEH
and 95 patients with NPC. High expression of SATB1
protein (IRS ≥6) was observed in the nucleus of 65.3%
of NPCs (62/95), compared to 33.3% (8/24) of patients
with NEH (P = 0.005) (Table 1, Figure 1), suggesting a
crucial role for SATB1 over-expression in NPC pathogen-
esis. We next analyzed the association of SATB1 expression
with the clinical parameters of NPC patients. While no cor-
relation was observed between SATB1 high expression and
patient gender, age or smoking condition, a positive correl-
ation with clinical classification (I-II vs III-IV, P = 0.025), N
classification (N0 vs N1-N3, P = 0.018) and M classification
(M0 vs M1, P = 0.041) was observed (Table 1). We also
observed an association between SATB1 expression and
T classification (T1-T2 vs T3-T4, P = 0.077), although this
was not statistically significant. Together these results
strongly indicate that high expression of SATB1 protein
contributes to the clinical progression of human NPC.Expression features of SATB1 in NPC and NP-69 cell lines
To further examine the relationship between SATB1 ex-
pression and NPC pathogenesis, we analyzed the expression
of SATB1 in three cell lines representing various differenti-
ation stages of NPC. As shown in Figures 2 and 3, the
expression of SATB1 mRNA and protein varied between
the different NPC cell lines. In general, we observed a very
low level of SATB1 expression in immortalized NP-69 cells,
which was predominantly localized in the cytoplasm. In
contrast, SATB1 expression was increasingly observed
in well-differentiated CNE1 cells, poorly-differentiated
CNE2Z cells and undifferentiated C666-1 cells. SATB1
mainly located in cytoplasm in CNE1 and CNE2Z cells, but
increasing nucleus location in C666-1 cells was observed
(Figure 3). These results suggest that SATB1 expression
is inversely associated with the cellular differentiation
status of NPC.
Inhibition of SATB1 attenuates NPC cell proliferation
To investigate the effect of SATB1 on NPC cell prolifera-
tion, we performed knockdown of SATB1 in C666-1 cells
using three independent siRNAs targeting the SATB1
coding region. Initial testing of these siRNAs revealed that
the cocktail of si-SATB1-1 and si-SATB1-2 displayed the
significant degree of SATB1 knockdown in C666-1 cells
(inhibitory rate >85%, data not shown), and this cock-
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Figure 6 Knock-down of SATB1 suppresses NPC cell migration. Cell migration was assessed 48 hours following transfection of CNE1, CNE2Z,
C666-1 cells and NP-69 with cocktails of SATB1 siRNA (si-SATB1), control siRNA (si-Control) or untransfected (MOCK) by Transwell migration assay.
Migrated cells present on the lower surfaces of the membranes were counted within fifteen representative fields in triplicate inserts. (A):
Representative photographs of cell migration. (B): Cell migration and percentages. the results indicating the percentage of cell migration were
plotted as the percentage over controls (MOCK). **P <0.01 vs Mock or si-Control-treated groups. Scale bars = 100 μM.
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blotting confirmed that transfection this siRNA cocktails to
NPC cells led to a significant decrease of SATB1 protein
expression, besides, attenuated PCNA protein expressions
were also observed (Figure 4). Then the cell proliferation
was examined by CCK-8 assays post transfection these 4
cell line with SATB1 specific siRNA cocktails. As shown in
Figure 5, transfection of the NPC cell lines with this siRNA
cocktails led to significantly damaged cell viability in CNE2Z
and C666-1 cells, but not the CNE1 and NP-69 cells. Taken
together, these results demonstrate that over-expression of
SATB1 plays a crucial role in NPC cell proliferation.
Inhibition of SATB1 represses NPC cell migration
Cervical lymph node metastasis is one of the most common
clinical symptoms of NPC patients at primary diagnosis[26], therefore blocking the migration of NPC cells may
represent a promising treatment strategy. Indeed, treatment
of highly SATB1-expressing CNE2Z and C666-1 cells with
SATB1-siRNAs led to a significant decrease in cell migra-
tion, while migration was unaffected in CNE1 cells and im-
mortalized NP-69 cells (Figure 6). These results suggest that
SATB1 over- expression in NPC cells promotes migration.
The association between LMP −1 and SATB1 expression
in NPC
Immunohistochemistry was used to assess LMP-1 ex-
pression in 95 clinical NPC samples. In the present in-
vestigation, we just divided NPC into LMP-1 positive
(LMP-1+, IRS ≥1) and LMP-1 negative (LMP-1-, IRS < 1)
groups. By this ways, there were 61.1% (58/95) NPC














Figure 7 LMP-1 expression in clinical NPC samples and NPC cell lines and its correlation to SATB1. (A) Representative photograph of
LMP-1 expression in NPC samples examined by immunohistochemistry (IRS >6.0). (B) Association between LMP-1 and SATB1 expression in clinical NPC
samples. (C) Immunofluorescence staining, (D) Western blotting and (E) RT-PCR were used to detect the LMP-1 expression in well-differentiated CNE1,
poorly-differentiated CNE2Z and un- differentiated C666-1 cell lines. β-actin was used as a loading control.
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A positive correlation of LMP-1 to SATB1 expression in
clinical NPC samples was appeared (r = 2.35, P < 0.01,
Figure 7). Further, we performed immunflurescent staining,
western blotting and RT-PCR analysis to assess LMP-1
expression in CNE1, CNE2Z and C666-1 cells lines. As
results, there were no obviously LMP-1 protein expressions
in three NPC cell lines, which were verified by results of
immunflurescent staining and western blotting, however,
the transcripts of LMP-1 could be notably detected in
C666-1 cells; interestingly, LMP-1 transcripts expression
levels in NPC cell lines were positively associated with
SATB1 mRNA expression (Figure 7). To further investigate
the relationship between LMP-1 and SATB1 in NPC
cells, a LMP-1 over-expression plasmid (PAT-LMP-1-GFP)
was transfected into CEN1 cells to generate LMP-1 stably
expressed NPC cell line CNE1-GL [31], then we found that
forced LMP-1 expression in CNE1 cells led to a surpris-
ingly increased SATB1 expression and nuclear location,
companying with the up-regulation of PCNA (Figure 8).Together these results referred that LMP-1 may mediate
SATB1 expression in NPC cells.
Discussion
SATB1 promotes tumor metastasis by providing a nuclear
architectural platform regulating the expression of >1000
genes, many of which are related to cell growth and
translocation [7]. In the present study, we detected
over-expression of SATB1 protein (IRS ≥6) in 65.3% of
NPCs (62/95), which was significantly higher than that
observed in benign NEH (8/24), suggesting that SATB1
may play a role in NPC pathogenesis. We then further
assessed the correlation between SATB1 protein over-
expression and NPC patient clinical parameters. We ob-
served that SATB1 protein over-expression was positively
correlated with clinical stage (P = 0.025), the status of lymph
node metastasis (N classification) (P = 0.018) and distant
metastasis (M classification) (P = 0.041). These data suggest
that high expression of SATB1 contributes to the clinical
progression of NPC. Our results are consistent with other
CNE1   CNE1-GL
LMP-1
β-actin

















Figure 8 LMP-1 induces SATB1 expression and nuclear location in NPC cells. CNE1 (LMP1-) and CNE1-GL (LMP1+, ectopic expression of EBV
LMP1 in CNE1 cells) cells were harvested and then (A) western blotting and (B) Immunofluorescence staining were used to detect LMP1
expression. (C) Immunofluorescence staining was used to detect SATB1 and PCNA proteins expression and its sub-cellular location. Antigens were
localized by FITC- or TRITC-conjugated IgGs. Scale bars = 100 μM.
Shen et al. Journal of Translational Medicine 2013, 11:217 Page 10 of 12
http://www.translational-medicine.com/content/11/1/217reports showing that high expression of SATB1 pro-
motes cancer progression in multiple human carcinomas
[7,11-14,17,19,32].
We next examined SATB1 expression in NPC cell
lines at various stages of differentiation. We found that
when compare with a basal levels of SATB1 expression
in the immortalized NP-69 cells, the well-differentiated
CNE1 cells displayed a low levels of SATB1 expression,
while the highly proliferative and poorly-differentiated
CEN2Z cells, and undifferentiated C666-1 cells exhibited
increasing SATB1 expression and a increase of nuclear
localization (Figure 2 and 3). These results indicate
that the expression of SATB1 is inversely correlated to
NPC cell differentiation. Our findings support the very
recent report of Barboro et al., demonstrating that SATB1,
a DNA matrix attachment regions (MARs) binding
protein, is involved in the differentiation of prostate can-
cer cells [33]. In the present study, SATB1 expression
co-localized with PCNA, a marker of cell proliferation,
in NPC cells (Figure 3). This is in accordance with a
study by Chu et al. [34], which showed that SATB1expression was positively correlated with Ki67 expres-
sion in gliomas.
In human epithelium-derived carcinoma cells such as
breast cancer cells, inhibition of SATB1 expression by
siRNA or Decoy-DNA led to reversal of cell malignancy
[7,32]. In addition, knockdown of SATB1 in human non-
epithelium- derived cancers such as U251 glioma cells also
led to inhibition of cell growth, invasion, metastasis and
angiogenesis [34]. These results highlight the possibility of
molecularly targeting SATB1 in cancer treatment. In this
study, we found that treatment of SATB1-expressing NPC
cells with SATB1-specific siRNAs, attenuated cell pro-
liferation and motility which verified by the changes of
expression of PCNA (Figure 4), cell viability (Figure 5) and
cell migration (Figure 6). Our results support the rationale
that targeting SATB1 may represent an alternative thera-
peutic strategy in the treatment of NPC.
NPC is an EBV associated malignant carcinoma, espe-
cially in endemic area such as Southern China. Previous
studies in our department focused on the role of the EBV-
encoded LMP-1 in the pathogenesis of NPC [31,35-38],
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cated that the LMP-1 could promote NPC progression. In
the present study, our preliminary data revealed that LMP1
expression was positively associated with SATB1 expression
in clinical NPC specimens (r = 2.35, P < 0.01); in addition,
the expression level of SATB1 was correlation with LMP-1
expression status in NPC cell lines (Figure 7); much inter-
estingly, ectopic expression of LMP-1 strongly promoted
SATB1 expression and its nuclear location, as well as an
up-regulation of PCNA, in well-differentiated CNE1 cells
(Figure 8). Combining results about the SATB1 expression
styles in CNE1, CNE2Z, C666-1 and CNE-GL cells and its
correlation to LMP-1 expression in clinical NPC samples,
it seemed that LMP-1 stimulates cell proliferation partly
via up-regulating of SATB1 expression in NPC cells.
The process of epithelial-to-mesnchymal transition
(EMT) is one of several key factors involved in tumor
metastasis. Previous reports have shown that NPC cells
have undergone the process of EMT [39-41], in particu-
lar the neoplastic spindle cells in NPC [40]. Our present
results showed that knockdown of STAB1 expression by
SATB1 specific siRNA led to an obvious up-regulation
of E-cadherin and a down-regulation of Vinmentin, the
marker for EMT (Additional file 2: Figure S1). These re-
sults therefore support previous reports regarding the role
of EBV infection in EMT in NPC [41-43]. Very recently, a
report of Endo K and colleagues had revealed that EBV
LMP1 could induce SATB1 expression in human NPC
[44]. Thus, we hypothesized that EBV may promote NPC
progression partly by modulation the process of EMT via
LMP1-mediated SATB1 expression.
Conclusions
Taken together, our study provides the evidence that EBV
LMP-1 expression may associate with SATB1 expression in
NPC; over-expression of SATB1 is closely related to the clin-
ical progression of NPC, SATB1 was universally expressed
in all NPC cell lines examined, and its expression levels were
inversely related with cell differentiation; knockdown
of SATB1 by specific siRNA led to attenuated cell prolif-
eration and migration. Our results highlight the possibility
of SATB1 as a promising biomarker and therapeutic target
for NPC. Future studies will focus on i) factors such as
LMP-1 controlling SATB1 expression in the NPC cells, ii)
the combination of factors working in concert with
SATB1 in NPC cells, and iii) investigating how SATB1
mediates the process of EMT in NPC cells.Additional files
Additional file 1: Primer pairs used for PCR.
Additional file 2: Figure S1. Knockdown of SATB1 in NPC cells lead to
changes of EMT marker genes.Abbreviations
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